Selected article for: "abdominal pain vomiting and acute sars infection"
Author: da Silva, Filipe Antônio França; de Brito, Breno Bittencourt; Santos, Maria Luísa Cordeiro; Marques, Hanna Santos; da Silva, Ronaldo Teixeira; de Carvalho, Lorena Sousa; Vieira, Elise Santos; Oliveira, Márcio Vasconcelos; de Melo, Fabrício Freire
Title: COVID-19 gastrointestinal manifestations: a systematic review
  • Cord-id: 6gjghyzw
  • Document date: 2020_11_25
    • ID: 6gjghyzw
    Snippet: INTRODUCTION: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has greatly challenged public health worldwide. A growing number of studies have reported gastrointestinal (GI) symptoms. We performed a systematic review of GI symptoms associated with coronavirus disease 2019 (COVID-19) as well as of the serum levels of biomarkers related to liver function and lesion in SARS-CoV-2-infected individuals. METHODS: We surveyed relevant articles published in
    Document: INTRODUCTION: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has greatly challenged public health worldwide. A growing number of studies have reported gastrointestinal (GI) symptoms. We performed a systematic review of GI symptoms associated with coronavirus disease 2019 (COVID-19) as well as of the serum levels of biomarkers related to liver function and lesion in SARS-CoV-2-infected individuals. METHODS: We surveyed relevant articles published in English, Spanish, and Portuguese up to July, 2020 in the PubMed, MEDLINE, SciELO, LILACS, and BVS databases. Moreover, we surveyed potentially important articles in journals such as the NEJM, JAMA, BMJ, Gut, and AJG. RESULTS: This systematic review included 43 studies, including 18,246 patients. Diarrhea was the most common GI symptom, affecting 11.5% of the patients, followed by nausea and vomiting (6.3%) and abdominal pain (2.3%). With regard to clinical severity, 17.5% of the patients were classified as severely ill, whereas 9.8% of them were considered to have a non-severe disease. Some studies showed increased aspartate transaminase and alanine aminotransferase levels in a portion of the 209 analyzed patients and two studies. CONCLUSIONS: Our results suggest that digestive symptoms are common in COVID-19 patients. In addition, alterations in cytolysis biomarkers could also be observed in a lesser proportion, calling attention to the possibility of hepatic involvement in SARS-CoV-2-infected individuals.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and abstract title: 1
    • abdominal pain and acute liver injury: 1, 2, 3, 4, 5
    • abdominal pain and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • abdominal pain and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • abdominal pain and liver level: 1
    • abdominal pain likely and liver function: 1
    • abdominal pain nausea vomiting and abnormal ast: 1
    • abdominal pain nausea vomiting and acute liver injury: 1, 2
    • abdominal pain nausea vomiting and liver enzyme: 1, 2, 3
    • abdominal pain nausea vomiting and liver function: 1, 2, 3, 4, 5, 6
    • abdominal pain nausea vomiting and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • abdominal pain prevalence and liver enzyme: 1
    • abdominal pain prevalence and liver injury: 1
    • abnormal ast and liver abnormality: 1, 2
    • abnormal ast and liver enzyme: 1, 2
    • abnormal ast and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • abnormal ast and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • abnormal ast and liver level: 1, 2